ResMed Inc. reported its Q4 2026 earnings results, which fell short of analysts' expectations. The company's revenue totaled $1.15 billion, a decrease of 4% from Q4 2025. In contrast, Zevia PBC reported a revenue increase of 12% in Q2 2026 compared to the same period in 2025, although its forecast for Q3 2026 fell short of expectations.
ResMed Inc.'s CEO, Mick Farrell, acknowledged the company's Q4 revenue miss during the earnings call. He stated that the company's sales growth in Q4 2026 was lower than expected due to a combination of factors, including increased competition and high production costs.
Zevia PBC's downbeat forecast for Q3 2026 has caused concerns among investors. Analysts note that the company's high production costs and increased competition in the low-calorie soda market are major contributors to this decline. The company's forecast for Q3 2026 fell short of expectations, leading many to question its future growth potential.
The mixed reports from ResMed Inc. and Zevia PBC are cause for caution. ResMed Inc.'s sales growth concerns and Zevia PBC's downbeat forecast casting a shadow over the performance of the companies in their respective industries. The investors remain cautious, with ResMed Inc.'s stock price experiencing a decline of 6% following the company's earnings report, while Zevia PBC's stock price is holding steady.